|[February 05, 2013]
Alnylam to Webcast Presentation at Upcoming Investor Conferences
CAMBRIDGE, Mass. --(Business Wire)--
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the 15th Annual BIO CEO & Investor Conference on Tuesday,
February 12, 2013 at 2:30 p.m. ET at the Waldorf Astoria in New York
In addition, Alnylam management will present a company overview at the
Leerink Swann Global Healthcare Conference 2013 on Wednesday, February
13, 2013 at 10:30 a.m. ET at the Waldorf Astoria in New York City.
A live audio webcast of the presentations will be available on the News
& Investors section of the company's website, www.alnylam.com.
A replay of the presentation will be available on the Alnylam website
within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylm is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is leading the
translation of RNAi as a new class of innovative medicines with a core
focus on RNAi therapeutics for the treatment of genetically defined
diseases, including ALN-TTR for the treatment of transthyretin-mediated
amyloidosis (ATTR), ALN-AT3 for the treatment of hemophilia and rare
bleeding disorders (RBD), ALN-AS1 for the treatment of acute
intermittent porphyria (AIP), ALN-PCS for the treatment of
hypercholesterolemia, and ALN-TMP for the treatment of
hemoglobinopathies. As part of its "Alnylam 5x15TM" strategy,
the company expects to have five RNAi therapeutic products for
genetically defined diseases in clinical development, including programs
in advanced stages, on its own or with a partner by the end of 2015.
Alnylam has additional partnered programs in clinical or development
stages, including ALN-RSV01 for the treatment of respiratory syncytial
virus (RSV) infection and ALN-VSP for the treatment of liver cancers.
The company's leadership position on RNAi therapeutics and intellectual
property have enabled it to form major alliances with leading companies
including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa
Hakko Kirin, Cubist, Ascletis, Monsanto, Genzyme, and The Medicines
Company. In addition, Alnylam holds a significant equity position in
Regulus Therapeutics Inc., a company focused on discovery, development,
and commercialization of microRNA therapeutics. Alnylam has also formed
Alnylam Biotherapeutics, a division of the company focused on the
development of RNAi technologies for applications in biologics
manufacturing, including recombinant proteins and monoclonal antibodies.
Alnylam's VaxiRNA™ platform applies RNAi technology to improve the
manufacturing processes for vaccines; GlaxoSmithKline is a collaborator
in this effort. Alnylam scientists and collaborators have published
their research on RNAi therapeutics in over 100 peer-reviewed papers,
including many in the world's top scientific journals such as Nature,
Nature Medicine, Nature Biotechnology, and Cell.
Founded in 2002, Alnylam maintains headquarters in Cambridge,
Massachusetts. For more information, please visit www.alnylam.com.
[ InfoTech Spotlight's Homepage ]